- Royalty Pharma is one of a handful of healthcare companies that I was interested in since they announced their IPO. The company is profitable and offers a dividend.
- Unlike other biopharma IPOs, Royalty's business is to buy biopharmaceutical royalties rather than take the money to develop a technology or push a drug through the FDA.
- Royalty is achieving success by simply buying the rights to royalties and recuperating the costs in the coming years.
- I was a bit skeptical at first, but the company has been in business with this model since 1999. I have confidence the company will continue to grow in the coming years with its current portfolio of royalties.
- I discuss the company’s valuation and risks. In addition, I reveal my investment strategy for RPRX as we move deeper into 2022.
For further details see:
Royalty Pharma Offers A Unique Long-Term Investment Opportunity